Systemic lupus erythematosus (SLE)

Molecular Insights from the Accelerating Medicines Partnership (AMP): Systemic Lupus Erythematosus

Sunday, November 8, 2020

10:00 AM – 11:00 AM ET

Moderator(s)

Deepak Rao, MD, PhD

Brigham and Women's Hospital

Speaker(s)

DH

David Hildeman, PhD

Cincinnati Children's Hospital
AA

Arnon Arazi, PhD

Feinstein Institutes for Medical Research
Andrea Fava, MD

Johns Hopkins University
Jill Buyon, MD

NYU School of Medicine

In Phase 2 of the Accelerating Medicines Partnership study of systemic lupus erythematosus, over 150 patients with lupus nephritis were recruited for collection of clinical measures as well as kidney biopsies, blood, serum and urine. Kidney biopsies are being analyzed by both whole cell single-cell RNA-seq and nuclear RNA-seq. Cells from peripheral blood are being analyzed by mass cytometry and single cell RNA-seq. Both cells and fluid from urine are been assayed for urine biomarkers of kidney disease. This session will discuss the methods used to generate data and present findings from the ongoing analyses of kidney and urine.

Participants should be aware of the following financial/non-financial relationships:
Deepak Rao, MD, PhD: Bristol-Myers Squibb: Consulting Fees (e.g., advisory boards); Celgene: Grant/Research Support; GlaxoSmithKline: Speaker/Honoraria; Janssen: Consulting Fees (e.g., advisory boards); Merck: Grant/Research Support; Pfizer: Consulting Fees (e.g., advisory boards); Scipher Medicine: Consulting Fees (e.g., advisory boards)
David Hildeman, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Arnon Arazi, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Andrea Fava, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jill Buyon, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Learning Objectives:

Review the methods used to analyze kidney biopsy samples by single cell RNA-seq
Discuss the immune and parenchymal cell features of lupus nephritis identified by single cell RNA-seq
Describe the abnormalities in urine of lupus nephritis patients identified by urine proteomics
Summarize the progress of the AMP SLE Network and its potential relevance in patient stratification and targeted therapy

Presentations:

10:00 AM – 10:10 AM ET

Getting Single Cell RNA-Sequencing Data From Human Kidney Biopsies
David Hildeman, PhD – Cincinnati Children's Hospital
10:10 AM – 10:20 AM ET

Single Cell Transcriptomic Analyses of Lupus Nephritis Kidney
Arnon Arazi, PhD – Feinstein Institutes for Medical Research
10:20 AM – 10:30 AM ET

Urine Proteomics in Lupus Nephritis: Implications for a Liquid Biopsy
Andrea Fava, MD – Johns Hopkins University
10:30 AM – 10:45 AM ET

What Have We Learned About SLE from AMP, and Where Are We Going?
Jill Buyon, MD – NYU School of Medicine
10:45 AM – 11:00 AM ET

Q&A